Top Companies in Respiratory Diagnostics Market

The global respiratory diagnostics market is projected to reach USD 9.02 billion by 2030 from USD 6.17 billion in 2024, at a CAGR of 6.5%. Growth in this market is largely driven by the increasing incidences of respiratory disorders like Chronic Obstructive Pulmonary Disorder (COPD), asthma, tuberculosis, lung cancer, and other pulmonary disorders. Further, there is an increase in the number of cigarette smokers, growing aging population and changing lifestyle, which are boosting the market growth.

The prominent players in the respiratory diagnostics market include Koninklijke Philips N.V. (Netherlands), Becton, Dickinson and Company (US), Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), GE Healthcare Technologies Inc. (US), Bio-Rad Laboratories, Inc. (US), Blomerieux (France), Revvity, Inc. (US), Seegene Inc. (South Korea), Nihon Kohden Corporation (Japan), Vitalograph (UK), SDI Diagnostics (US), ResMed Inc. (US), Siemens Healthineers AG (Germany), Cosmed srl (Italy), Hologic, Inc. (US),  and Qiagen N.V. (Germany). These players are constantly involved in the development of new products and adopting growth strategies like acquisitions, mergers, collaboration, etc. to strengthen their market reach.

To know about the assumptions considered for the study download the pdf brochure

Koninklijke Philips N.V.

The Koninklijke Philips N.V. is structured into four business lines that are: Diagnostic and Treatment, Personal Health, Connected Care, and Other. The Connected Care line consists of Hospital and Patient Monitoring, Emergency Care, Sleep & Respiratory Care, and Connected Care Informatics. The company's area under Sleep & Respiratory Care develops respiratory diagnostics products and solutions to be marketed. The company provides more than 450 products and services across over 120 countries, with its international workforce of approximately 40,099 people. Some of the key subsidiaries are Philips Respironics GK (Japan), Philips Medical Systems Technologies Ltd. (Israel), Respironics do Brasil (Brazil), Respironics Medical Products (Shenzhen) Ltd. (China), Respironics Deutschland (Germany), Respironics (Ireland), Respironics Sweden AB (Sweden), Respironics (UK) Ltd., and Respironics, Inc. (US). Philips in January 2024, signed an agreement with 4DMedical Limited (Australia) on a 5-year distribution agreement to retain exclusive access to its product for customers of the United States' government, but retains the non-exclusive right for its other commercial customers. Philips launched the CT 3500, an AI-assisted device diagnostic device in May 2023 with advanced imaging features and improved workflow that aid in more rapid and more accurate diagnosis.

GE Healthcare Technologies Inc.

GE Healthcare is at the forefront in medical technology and digital solutions enabling clinicians through data analytics, intelligent devices, applications, and services for diagnosis, treatment, and monitoring of patients. It offers accessories, education, services, consumables, and training and consulting. The business operates in five segments: healthcare, aerospace, power, renewables, and corporate. The healthcare segment is further broken into healthcare systems and pharmaceutical diagnostics, where the latter has products and services relating to respiratory diagnostics. It has over a century-long experience in the healthcare domain and has a presence in over 170 countries through its subsidiaries such as GE Healthcare Danmark A/S (Denmark), GE OEC Medical Systems GmbH (Germany), GE Healthcare BV (Netherlands), and GE Healthcare Dharmacon, Inc. (US). In 2024, GE Healthcare completed an upgrade to its OEC 3D m-CBCT platform with the introduction of Lung Suite, which focuses on enhancement of workflow and visualization for clinicians during bronchoscopy procedures. In early January 2024, Wipro GE Healthcare, a joint venture of GE Healthcare LLC (US) and Wipro Enterprises Limited (India), announced the signing of a Memorandum of Understanding with the Indian Institute of Science (IISc) to accelerate research and innovation and technology development in healthcare in India.

BD

BD (Becton, Dickinson and Company) is a global medical technology company that manufactures and distributes medical devices, instrument systems, and reagents. Its three business segments are Medical, Life Sciences, and Interventional. Respiratory diagnostics solutions though come up in Life Science in two sub-segments: Integrated Diagnostic Solutions and Biosciences. BD markets to healthcare institutions, life science researchers, clinical laboratories, and the pharmaceutical industry, with sales in more than 50 countries across North America, Europe, Asia, the Middle East, and Africa. In August 2023, BD announced it had received FDA 510(k) clearance for BD Respiratory Viral Panel (RVP) for the BD MAX System, a molecular diagnostic test for identifying and differentiating SARS-CoV-2, influenza A, influenza B, and RSV in about two hours. Also in September 2024, BD acquired Edwards Lifesciences Corporations’ (US) Critical Care product group for USD 4.2 billion, branding it BD Advanced Patient Monitoring and thus expanding its offering of smart connected care solutions and opening up new value creation opportunities.

Related Reports:

Respiratory Diagnostics Market by Product & Services (Instrument & Devices), Test type (Mechanical, OSA, Imaging, Molecular Test), Disease (Tuberculosis, COPD, Lung Cancer ) and Diagnosis Type (Syndromic, Aetiological, Prognosis) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com